title: Treatment of mid-late stage NSCLC using sodium cantharidinate/vitamin B6/GP regimen in clinic.
abstract: OBJECTIVE
  The present study observed the clinical outcomes of the sodium cantharidinate/vitamin B6/GP regimen in the treatment of middle-late stage Non-small-cell lung carcinoma (NSCLC).
  
  
  METHODS
  Eighty-six cases of NSCLC were selected and randomized into two groups. Forty-five cases in the treatment group were subject to 30 ml cantharidinate/vitamin B6+ GP regimen, for four 21-day cycles. Forty-one cases in the control group were subject to regular GP regimen, for four 21-day cycles.
  
  
  RESULTS
  The effectiveness rate was 57.8% in the treatment group and 36.6% in the control group, suggesting statistical difference (P < 0.05); life quality in the treatment group was significantly better than that in the control group (P < 0.05); the occurrence rate of the toxic/adverse effects were significantly lower in the treatment group compared with that in the control group (P < 0.05).
  
  
  CONCLUSIONS
  Sodium cantharidinate/vitamin B6/GP regimen had fair effectiveness and synergistically improved the clinical outcomes. It lowered the toxic/adverse effects and its application is worth further investigation and promotion.
authors.forename: Baoli
authors.initials: B
authors.lastname: Wang
authors.affiliation: Department of Oncology, 303rd Hospital of People's Liberation Army, Nanning, Guangxi, China.
authors.forename: Jiandong
authors.initials: J
authors.lastname: Cui
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002193:Cantharidin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D002681:China; D064420:Drug-Related Side Effects and Adverse Reactions / Q000473:pathology; D006801:Humans; D009367:Neoplasm Staging; D011788:Quality of Life; D016896:Treatment Outcome; D025101:Vitamin B 6 / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: C027130:disodium cantharidin; D025101:Vitamin B 6; D002193:Cantharidin